Certainly no reason to think Anavex is working with Eisai due to a publication of years old data that Hampel worked on before he left the anavex board. Martin Farlow of NTRP signs off on research he helped in with many companies, including the paper that showed M1 stimulation has no effect on cognition. Jeff Cummings signed off on the M1 paper too btw.
Fact is after looking at the AVXL publication yesterday, it would scare me to death banking on AD. Out of the original 32 patients, 8 dropped out and only 21 had the slice and dice post hoc data done. Of that 21, only 2 improved at all and 4 more broke even for a year before falling off and the rest were essentially what the historical SOC was ESTIMATED to be and several groups did WAY WORSE that SOC. Repeat 19 of 21 (really 32 that started) did worse on the "homeostatic" miracle drug.
After reading the publication I see why the company spent millions and delayed trials for another year+ to try to find anything to keep the hope alive. The drug is essentially producing the same results as Aricept and in some cases worse. F1ash has posted multiple times the charts showing what you would expect to happen in these trials of mild patients over time and this publication mimics it to a tee. In fact in that population you would expect a few to improve, many to stay the same for over a year, and the rest to fall off. I truly hope Anavex shows promise for PDD and Rett and even AD, but we are talking a really long road on the AD front. Hopefully PDD is a success this summer. All is JMHO
Market Data 
Markets 
AI
